- Home
- KROS vs PCRX Comparison
KROS vs PCRX Comparison
Compare KROS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- PCRX
- Stock Information
- Founded
- KROS 2015
- PCRX 2006
- Country
- KROS United States
- PCRX United States
- Employees
- KROS N/A
- PCRX N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- PCRX Health Care
- Exchange
- KROS Nasdaq
- PCRX Nasdaq
- Market Cap
- KROS 558.9M
- PCRX 1.2B
- IPO Year
- KROS 2020
- PCRX 2011
- Fundamental
- Price
- KROS $14.53
- PCRX $22.90
- Analyst Decision
- KROS Buy
- PCRX Buy
- Analyst Count
- KROS 13
- PCRX 8
- Target Price
- KROS $20.63
- PCRX $28.38
- AVG Volume (30 Days)
- KROS 477.3K
- PCRX 545.0K
- Earning Date
- KROS 08-06-2025
- PCRX 07-29-2025
- Dividend Yield
- KROS N/A
- PCRX N/A
- EPS Growth
- KROS N/A
- PCRX N/A
- EPS
- KROS 0.11
- PCRX N/A
- Revenue
- KROS $214,713,000.00
- PCRX $702,772,000.00
- Revenue This Year
- KROS $5,006.76
- PCRX $7.54
- Revenue Next Year
- KROS N/A
- PCRX $10.78
- P/E Ratio
- KROS $132.80
- PCRX N/A
- Revenue Growth
- KROS 91657.70
- PCRX 3.08
- 52 Week Low
- KROS $9.12
- PCRX $11.16
- 52 Week High
- KROS $72.37
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- KROS 64.67
- PCRX 35.82
- Support Level
- KROS $13.26
- PCRX $22.82
- Resistance Level
- KROS $14.68
- PCRX $23.83
- Average True Range (ATR)
- KROS 0.41
- PCRX 0.74
- MACD
- KROS 0.12
- PCRX -0.02
- Stochastic Oscillator
- KROS 89.35
- PCRX 6.22
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.